Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome. Issue 10 (21st May 2021)

• Record Type: Journal Article
• Authors: Yanir, Asaf D.; Krauss, Aviva; Stein, Jerry; Steinberg‐Shemer, Orna; Gilad, Oded; Lotan, Sharon Noy; Dgany, Orly; Krasnov, Tatyana; Kodman, Yona; Feuerstein, Tamar; Mardoukh, Jacques; Fishman, Hila; Geron, Ifat; Yacobovich, Joanne; Tamary, Hannah; Birger, Yehudit; Avrahami, Galia; Izraeli, Shai; Birenboim, Shlomit Barzilai
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 10(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-21
• Subjects: hematopoietic stem cell transplantation -- inflammatory manifestations -- JMML -- myelodysplastic syndromes -- PTPN11; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29138
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Inflammatory manifestations (IM) are well described in adult patients with myelodysplastic syndrome (MDS), but the presentation is highly variable and no standardized treatment exists. This phenomenon is rarely reported in children. As more pediatric patients are hematopoietic stem cell transplantation (HSCT) candidates, the role of anti‐inflammatory treatment in relation to HSCT should be defined. Procedure: Here, we report a series of five children from a tertiary center. We describe the clinical presentation, molecular findings, and treatment options. Results: All patients presented with advanced MDS with blast percentages ranging 10–30%, all had severe IM. One patient had MDS secondary to severe congenital neutropenia, the other four patients had presumably primary MDS. All four were found to harbor a PTPN11 gene driver mutation, which is found in 35% of cases of juvenile myelomonocytic leukemia (JMML). The mutation was present in the myeloid lineage but not in T lymphocytes. Three had symptoms of Behcet's‐like disease with trisomy 8 in their bone marrow. All patients were treated with anti‐inflammatory medications (mainly systemic steroids) in an attempt to bring them to allogeneic HSCT in a better clinical condition. All demonstrated clinical improvement as well as regression in their MDS status post anti‐inflammatory treatment. All have recovered from both MDS and their inflammatory symptoms post HSCT. Conclusion: Primary pediatric MDS with IM is driven in some cases by PTPN11 mutations, and might be on the clinical spectrum of JMML. Anti‐inflammatory treatment may reverse MDS progression and improve the outcome of subsequent HSCT.